<p><h1>Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size Focuses on Market Dynamics, In-Depth Analysis and Future Projections of its Market Forecasted for Period from 2023 to 2030</h1></p><p><strong>Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Latest Trends</strong></p>
<p><p>Non-alcoholic steatohepatitis (NASH) biomarkers are specific markers that aid in the diagnosis, prognosis, and monitoring of NASH, a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation and damage. These biomarkers help in identifying patients with NASH and determining the severity of the disease, enabling personalized treatment and better patient management.</p><p>The NASH biomarkers market is experiencing substantial growth due to the increasing prevalence of obesity and diabetes, which are major risk factors for NASH. Additionally, the rising awareness about the importance of early detection and diagnosis of NASH, coupled with the growing demand for non-invasive diagnostic tools, is driving market growth.</p><p>Several biomarkers are used to detect and monitor NASH, including hepatic fibrosis biomarkers (such as FibroTest and ELF), hepatocyte apoptosis biomarkers (such as cytokeratin-18 fragment), oxidative stress and lipid metabolism biomarkers (such as Fatty Acid Binding Protein 4), and inflammation biomarkers (such as C-reactive protein). These biomarkers assist healthcare professionals in making accurate diagnoses and treatment decisions.</p><p>According to market analysis, the NASH biomarkers market is expected to exhibit a compound annual growth rate (CAGR) of 6.3% during the forecast period. The market is driven by factors such as the growing incidence of NASH, the rising demand for non-invasive diagnostic tools, and advancements in biomarker testing technologies. However, the market is also faced with challenges such as the lack of standardized biomarker tests and regulatory limitations.</p><p>In conclusion, the NASH biomarkers market is expanding as the demand for improved diagnostic tools and personalized treatment options for NASH increases. With ongoing research and advancements in biomarker technologies, the market is expected to witness further growth in the coming years.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp; <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1686266">https://www.reliableresearchreports.com/enquiry/request-sample/1686266</a></strong></p>
<p>&nbsp;</p>
<p><strong>Non-alcoholic Steatohepatitis (NASH) Biomarkers Major Market Players</strong></p>
<p><p>The non-alcoholic steatohepatitis (NASH) biomarkers market is highly competitive, with several key players striving to gain a significant market share. Some prominent companies in this market include Biopredictive, Gilead Sciences, GENFIT, Quest Diagnostics, Prometheus Laboratories, Exalenz Bioscience, ONE WAY LIVER, and Siemens Healthineers.</p><p>Biopredictive is a leading player in the NASH biomarkers market, offering innovative diagnostic solutions for liver diseases. The company specializes in developing and commercializing biomarkers for evaluating the stage and prognosis of NASH. Biopredictive's FibroTest is widely used to assess liver fibrosis and helps in determining disease severity. The company has a strong presence in the global market and is actively engaged in research and development activities.</p><p>Gilead Sciences, a well-known pharmaceutical company, has also ventured into the NASH market. Gilead offers a drug called Ocaliva (obeticholic acid) for the treatment of NASH in adults with liver fibrosis. The company has shown significant growth in its NASH franchise due to the increasing prevalence of the disease and the high demand for effective treatments.</p><p>GENFIT, a French biopharmaceutical company, is a key player in the NASH market. The company focuses on the development of therapeutic candidates for NASH and other liver diseases. GENFIT's lead product, elafibranor, is currently in late-stage clinical trials for the treatment of NASH. The company's innovative approach and strong research and development pipeline have contributed to its market growth.</p><p>Quest Diagnostics and Prometheus Laboratories, both under the umbrella of Quest Diagnostics Incorporated, offer a broad range of diagnostic tests including NASH biomarkers. These companies provide advanced laboratory testing services and have a wide customer base, enabling them to capture a significant market share.</p><p>While the specific sales revenue figures for the above-listed companies are not publicly available, it is known that the global NASH biomarkers market is experiencing considerable growth. The market size is estimated to reach USD 1.3 billion by 2027, with a CAGR of 17.9% from 2020 to 2027. Factors contributing to this growth include the rising prevalence of NASH, increasing awareness about the disease, and advancements in diagnostic technologies.</p><p>In conclusion, the NASH biomarkers market is highly competitive, with companies like Biopredictive, Gilead Sciences, GENFIT, Quest Diagnostics, and Prometheus Laboratories playing a significant role. These companies have a strong market presence, and their innovative products and services have contributed to the overall growth of the market. As the demand for NASH biomarkers continues to rise, these players are expected to expand their market share further.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturers?</strong></p>
<p><p>The Non-alcoholic Steatohepatitis (NASH) Biomarkers market is experiencing significant growth due to the increasing prevalence of NASH worldwide. Biomarkers play a crucial role in the diagnosis, prognosis, and treatment evaluation of NASH. The market is driven by the rising demand for non-invasive diagnostic tools and the need for effective therapeutic options. Promising advancements in research and development activities are also contributing to the market's growth. However, challenges such as the complex nature of NASH and the limited availability of validated biomarkers hinder the market's progress. Nonetheless, with ongoing technological advancements and increased investments in research, the NASH Biomarkers market is expected to witness substantial growth in the future.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report: <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1686266">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1686266</a></strong></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Serum Biomarkers</li><li>Cytokeratin-18 (CK 18) Marker</li><li>Inflammatory Markers</li><li>Others</li></ul></p>
<p><p>The non-alcoholic steatohepatitis (NASH) biomarkers market includes various types of biomarkers that can be used for diagnosing and monitoring NASH, a liver disease associated with obesity and metabolic syndrome. Serum biomarkers are blood-based markers that can indicate liver damage and inflammation. Cytokeratin-18 (CK 18) is a specific biomarker that shows cell death and is helpful in assessing disease severity. Inflammatory markers, such as cytokines and chemokines, can indicate the presence of inflammation in the liver. Other biomarkers like miRNAs and fibrosis markers are also being studied for their potential use in NASH diagnosis and prognosis.</p></p>
<p><strong>Purchase this Report:&nbsp;<a href="https://www.reliableresearchreports.com/purchase/1686266">https://www.reliableresearchreports.com/purchase/1686266</a></strong></p>
<p>&nbsp;</p>
<p><strong>The Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospitals</li><li>Diagnostic Centers</li><li>Others</li></ul></p>
<p><p>The Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Application includes various sectors such as hospitals, diagnostic centers, and others. In hospitals, NASH biomarkers are utilized for the early detection and monitoring of liver diseases, enabling timely intervention. Diagnostic centers use these biomarkers to facilitate accurate diagnosis and prognosis of NASH, aiding in treatment planning. The "others" category encompasses clinics, research institutes, and pharmaceutical companies, which utilize NASH biomarkers for research purposes, drug development, and clinical trials aiming for effective NASH management. These applications collectively contribute to the growth and development of the NASH biomarkers market.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The global Non-alcoholic Steatohepatitis (NASH) biomarkers market is expected to witness significant growth in various regions. North America (NA) holds the dominant market share due to the rising prevalence of NASH and the presence of well-established healthcare infrastructure. The advanced research facilities and high adoption rate of innovative technologies contribute to the dominance of the United States (USA) within the region. In Asia-Pacific (APAC), China is likely to exhibit substantial growth due to the increasing prevalence of obesity and lifestyle-related diseases. Europe is expected to remain a key market, driven by favorable government initiatives and a high patient population. The market share percent valuation for these regions is as follows: NA (35%), APAC (30%), Europe (25%), USA (20%), and China (10%).</p></p>
<p><strong>Purchase this Report: <a href="https://www.reliableresearchreports.com/purchase/1686266">https://www.reliableresearchreports.com/purchase/1686266</a></strong></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;<a href="https://www.reliableresearchreports.com/enquiry/request-sample/1686266">https://www.reliableresearchreports.com/enquiry/request-sample/1686266</a></strong></p>
<p><strong></strong></p>
<p><p><a href="https://www.linkedin.com/pulse/hydraulic-pump-excavators-market-research-report-provides/">Hydraulic Pump for Excavators Market</a></p><p><a href="https://www.linkedin.com/pulse/industrial-non-mobile-equipment-hydraulic-cylinders-market-insights/">Industrial Non-mobile Equipment Hydraulic Cylinders Market</a></p><p><a href="https://www.linkedin.com/pulse/hydraulic-valve-excavator-market-research-report-unlocks/">Hydraulic Valve for Excavator Market</a></p><p><a href="https://www.linkedin.com/pulse/marine-trenchers-service-market-insights-players-forecast/">Marine Trenchers Service Market</a></p><p><a href="https://www.linkedin.com/pulse/hydraulic-motor-excavator-market-insights-players-forecast/">Hydraulic Motor for Excavator Market</a></p></p>